Everest Medicines is listed on the Hong Kong stock exchange (HKEX 1952.HK), and has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.

The company initiated commercial operations in 2021.